In a deal that will enhance its burgeoning Inflammation and Immunology portfolio, Celgene has agreed to acquire Receptos for a purchase price of approximately US$7.2 B in cash. The deal adds the Phase III oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod as well as a number of earlier stage programmes, including a Phase II antibody foreosinophilic oesophagitis.Ozanimod has thus far demonstrated potential advantage over existing oral therapies for ulcerative colitis and relapsing multiple sclerosis, including in terms of its cardiac and hepatotoxicity profile.